Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
The shocking rise in health complications linked to weight-loss drugs like Ozempic has ignited a fierce debate about the efficacy and safety of these medications. Originally designed as diabetes ...
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Feb. 21, the Food and Drug Administration said there is no longer a short supply of the weight loss and diabetes drugs Wegovy ...
High-end brands are churning through creative directors as they try to revive sales.
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results